Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: A review

Research output: Contribution to journalReview article

34 Scopus citations

Abstract

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer morbidity and mortality. Adjuvant chemotherapy improves survival in resected early-stage NSCLC. However, a significant proportion of patients with early-stage lung cancer are cured by surgery alone. There are no reliable clinical or molecular markers to predict outcomes after surgery in early-stage NSCLC. Positron emission tomography with 2-[F]fluoro-2-deoxy-D-glucose (FDG-PET) improves the accuracy of staging work-up in NSCLC. The standardized uptake value, a commonly used semiquantitative measure of FDG uptake, correlates with tumor doubling time and indices of cell cycling. Therefore, FDG-PET may be a useful predictor of outcome independent of its role in tumor staging. In this review, we critically examine the published studies on the utility of FDG-PET as a prognostic tool in patients with NSCLC and provide direction for future research.

Original languageEnglish
Pages (from-to)152-159
Number of pages8
JournalJournal of Thoracic Oncology
Volume1
Issue number2
DOIs
StatePublished - Feb 1 2006

Keywords

  • 2-[F]fluoro-2-deoxy-D-glucose positron emission tomography
  • Non-small cell lung cancer
  • Prognosis

Fingerprint Dive into the research topics of 'Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: A review'. Together they form a unique fingerprint.

  • Cite this